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		ABSTRACT		Exosomal	non-coding	RNAs	were	explored	as	a	basis	for	monitoring	breast-cancer	patients.	Specifically,	exosomal	microRNAs	(miRNAs),	and	especially	miR-21,	were	the	focus	of	this	project.	Consistent	with	our	hypothesis,	we	found	that	miR-21	was	 highly	 expressed	 in	 exosomes	 of	 cancer	 patients	 compared	 to	 ‘healthy’	individuals.	However,	circulating	miR-21	levels,	when	compared	in	post-	versus	pre-surgery	 serum,	 did	not	 decline	 for	 all	 five	 experimental	 patients.	 This	 unexpected	observation	 could	be	 the	 result	 of	 small	 sample	 size	 and	 lack	of	both	endogenous	and	exogenous	miRNA	controls.		All	five	patients	had	early	stage	breast	cancer.		We	found	 that	 our	methods	 were	 possibly	 not	 sensitive	 enough	 to	 detect	 very	 small	differences	 between	 pre-	 and	 post-surgery	 serum.	 	 Future	 experiments	 might	involve	 samples	 at	 a	 later	 stage	 of	 cancer.	 	 High	 miR-21	 levels	 in	 post-tumor	resection	serum	raised	an	issue	concerning	how	long	cancerous	exosomes	can	stay	in	the	blood	after	tumor	removal.	 	As	well,	recovery	time	from	surgery	might	vary	from	 patient	 to	 patient.	 Consequently,	 additional	 serum	 samples	 from	 patients	might	be	obtained	at	 a	 later	 time	after	 surgery.	 	This	 research	 signals	 an	advance	over	 current	 modes	 of	 cancer	 detection	 and	 involves	 a	 more	 patient-centric	approach.	 Customized-miRNA	 panels	 might	 someday	 be	 the	 standard	 for	 each	breast-cancer	patient.	The	release	of	breast-tumor	exosomes	and	their	miRNA	cargo	
		 iv	
into	 the	blood	stream	allow	for	disease	detection	by	way	of	non-invasive	methods	achieved	at	 lower	application	costs.	This	technology,	with	all	 its	advantages,	might	result	 in	 more	 frequent	 screenings	 of	 patients	 and	 thus	 an	 earlier	 detection	 of	cancer	and	more	efficient	patient	care.																					
		



























































































































































































































































1	 50	 54.2	 87	
2	 50	 56.1	 94	
3	 50	 41.5	 105	
4	 50	 30.5	 98	
5	 150	 38.1	 120	
6	 300	 52.4	 86	
7	 150	 58.4	 97	
8	 50	 48.8	 105	
9	 50	 38.3	 89	














































































































































































































































		 		 		 		 		 		 		 		 		
2Z2HMP	 -11	 11	 68	 1	 1A	 T1a 	 N0 	 M0 	
JQE6NC	 -16	 11	 63	 1	 1A	 T1b 	 N0 	 M0 	
		 		 		 		 		 		 		 		 		
PJREBY	 -18	 9	 45	 2	 1B	 T1c 	 N1mi 	M0 	
93WMMV	 -24	 26	 79	 3	 1A	 T1c 	 N0 	 M0 	
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